Cancer Diagnostics Firm Nucleix Plans European Market Expansion
Cancer diagnostics company Nucleix is planning to scale up commercial activities in Europe for its bladder test Bladder EpiCheck. The Israeli firm told Medtech Insight it is currently in advanced negotiations with distributors to expand the test's commercial reach.
You may also be interested in...
The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.